Imbed Biosciences is a privately held medical device company focused on next-generation wound-care solutions built on its proprietary SAM™ (Synthetic Antimicrobial Matrix) Technology. The platform embeds multiple therapeutic agents into ultra-thin, biocompatible matrices that simultaneously lower bioburden and promote cellular proliferation, aiming for zero wound-care complications. Its flagship Microlyte® product targets chronic wound indications and is positioned as the only fully synthetic, antimicrobial skin-substitute on the market. Clinical evidence cited by the company shows the material supports scaffolding during healing while reducing infection and pain. Imbed plans to expand adoption in U.S. physician office settings and broaden its product portfolio for both chronic and acute wounds. The recent strategic backing is expected to accelerate R&D and commercial reach. No financial performance metrics or revenue figures were disclosed in the announcement.

Total raised

$16M

Funding rounds

5

Latest round

Convertible Note

Latest activity

Jan 2024